AstraZeneca’s Strategic Leap into KRAS G12D with Chinese Biotech Collaboration

November 28, 2023

Bavarian Nordic Sells FDA Priority Review Voucher for $160 Million Following Vimkunya Approval

June 19, 2025

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

June 25, 2022

Must Read

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

July 25, 2026

Top 10 Reasons Drug Development Timelines Remain Difficult to Compress

July 25, 2026

The Future of AI-Assisted Clinical Operations

July 24, 2026

About Us

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Summit and Akeso Report Updated HARMONi Survival Data for Ivonescimab in Western NSCLC Patients

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

Biogen’s Phase 2 Diranersen Data Shows Reduced Cognitive Decline in Alzheimer’s Disease

ARPA-H Awards Up to $160 Million for Personalized Genetic Medicine Development

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Due to poor phase 2 data, Agios declares goodbye to the sickle cell program

Novartis Lets Go of Phase 2 Radioligand Therapy Following Clinic Disappointment

Bausch + Lomb Ends BL1107 Glaucoma Program After Phase 2 Trial Misses Main Goal

BeOne Invests $300 Million to Add Small Molecule Manufacturing at New Jersey Campus

GSK views the Hansoh-partnered ADCs’ phase 3 victory in China as confirming its “priority asset.”

Vogenx Files for a Nasdaq Capital Market IPO to Fund Metabolic Drug

J&J’s OTTAV Robotic Surgical System has received FDA market authorization in the U.S.

Alnylam Inks $2B Agreement With Inceptive to Change sIRNA Design With AI Leader

Chugai and Gero Partner to Develop Antibodies for Age-Related Diseases Using AI

J&J MedTech presents the first Ottava surgical robot clinical cases

The Future of AI-Assisted Clinical Operations

The End of Siloed Drug Development

Top 10 Reasons Commercial AI Requires Stronger Governance in Pharma

Top 10 Metrics Pharma Leaders Should Track During Digital Transformation

Tag: Myeloma

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Editor Picks

AstraZeneca’s Strategic Leap into KRAS G12D with Chinese Biotech Collaboration

Bavarian Nordic Sells FDA Priority Review Voucher for $160 Million Following Vimkunya Approval

Zealand Pharma and Iktos collaborate to develop AI Technology for Peptide drug design

Must Read

J&J’s Bispecific Combination Works Wonders on Myeloma Progression in Phase 3 Study

Top 10 Reasons Drug Development Timelines Remain Difficult to Compress

The Future of AI-Assisted Clinical Operations

Hot Topics

About Us

Follow Us